Gonadal function in men with testicular cancer.
This article reviews current knowledge on the effect of testicular germ cell cancer (TGCC) on gonadal function and of the cancer treatment on spermatogenesis and Leydig cell function. It seems likely that development of TGCC shares common etiological factors with development other types of testicular dysfunction. This suggestion is supported by the observation that men with various types of gonadal dysfunction such as testicular dysgenesis, androgen insensitivity syndrome, and cryptorchidism have increased risk of testicular cancer. Epidemiological and clinical data indicate common etiology between testicular germ cell cancer and other abnormalities in male reproductive health such as infertility and cryptorchidism. These observations are in agreement with the suggestions of hormonal involvement in the etiology of testicular cancer. It is well documented that testicular cancer is associated with impaired spermatogenic function and some patients have impairment of Leydig's cell function already before orchidectomy. The degree of spermatogenic dysfunction is higher than what can be explained by local tumor effect and by a general cancer effect. These observations are supported by histological investigations, which have shown a high prevalence of abnormalities of spermatogenesis in the contralateral testis in patients with unilateral TGCC. The spermatogenetic function is still severely impaired after orchidectomy and radiotherapy as well as chemotherapy induce further dose-dependent impairment of spermatogenesis. Recovery of spermatogenesis after treatment may be long, in some patients lasting more than 5 years. Sufficient androgen production is seen in the majority of the patients but some patients do suffer from testosterone deficiency. The effect of chemotherapy on Leydig's cell function seems to be dose dependent. Trials on protection of spermatogenetic function against the harmful effects of radiotherapy and chemotherapy by suppression of spermatogenesis has not been successful. The only way to maintain fertility is to limit gonadal exposure to harmful agents. Moreover cryopreservation of semen should be done before treatment. The optimal time for cryopreservation is before orchiectomy at least in some patients. Generally men with TGCC need counselling about their reproductive function, with respect to semen cryopreservation, chance for recovery of spermatogenesis, fertility, and the possibility of need for androgen replacement.
Petersen
P M
PM
Department of Growth and Reproduction, Finsencenter, Copenhagen University Hospital, Rigshospitalet, Denmark.
Giwercman
A
A
Skakkebaek
N E
NE
Rørth
M
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D005298:Fertility / Q000187:drug effects / Q000528:radiation effects; D018237:Germinoma / Q000473:pathology / Q000503:physiopathology* / Q000628:therapy*; D006801:Humans; D007985:Leydig Cells / Q000187:drug effects / Q000473:pathology / Q000528:radiation effects; D008197:Lymph Node Excision; D008297:Male; D009919:Orchiectomy; D011878:Radiotherapy / Q000009:adverse effects; D013091:Spermatogenesis / Q000187:drug effects / Q000528:radiation effects; D013736:Testicular Neoplasms / Q000473:pathology / Q000503:physiopathology* / Q000628:therapy*